Ilaris Approved for Expanded Indications in 3 Rare Diseases
Editor’s Note: Target Health Inc. is very active in the rare/orphan disease area with FDA marketing approvals in Gaucher disease and Cystic Fibrosis. Dr. Jules Mitchel, President of Target Health Inc. will be participating in a panel at the NORD meeting in Washington October 17-18, 2016.
The FDA has approved Ilaris (canakinumab) for 3 new indications for the following rare and serious auto-inflammatory diseases in adult and pediatric patients:
All three syndromes are hereditary diseases that are characterized by periodic attacks of fever and inflammation, as well as severe muscle pain. There are no previously approved therapies for TRAPS or HIDS/MKD.
Ilaris was previously approved for another periodic fever syndrome called Cryopyrin-Associated Periodic Syndromes (CAPS) and for active systemic juvenile idiopathic arthritis. Approvals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data. The most common adverse reactions for these indications are injection site reactions and being more susceptible to catching colds.
Ilaris can cause serious side effects, including increased risk of serious infections as iIlaris can lower the immune system’s ability to fight infections. Other serious side effects include decreased ability to fight infections (immunosuppression) and allergic reactions. Patients experiencing any symptoms of an allergic reaction should call their healthcare provider, including: rash, itching and hives, difficulty breathing or swallowing, and dizziness or feeling faint. Patients should not get live vaccines if receiving Ilaris. Patients should not receive Ilaris if they are allergic to canakinumab or any of the ingredients in Ilaris.
Ilaris is manufactured and distributed by Novartis Pharmaceuticals Corporation, of East Hanover, New Jersey.